February 15th 2025
Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Oncology Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Atezolizumab Can Now Be Used Frontline in Cisplatin-Ineligible Bladder Cancer
April 18th 2017The Food and Drug Administration (FDA) granted an accelerated approval to atezolizumab (Tecentriq) to be used as a frontline treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma (mUC).
Nowhere to Turn: Cancer-Related Problems with Sexual Health or Fertility
February 20th 2017Leslie R. Schover, founder of the Will2Love online resources, discusses the sexual health and fertility issues that can come as a result of cancer treatment, and how these issues can be managed. Join us for our #CureConnect tweetchat, Tuesday 2/21, on this topic.
Shorter Radiotherapy Course Viable, Safe, and Cost-Saving in Low-Risk Prostate Cancer
October 17th 2016Deborah Watkins Bruner, RN, PhD, FAAN, discusses the results of a trial comparing quality of life after conventional radiotherapy and after a hypofractionated schedule for men at low-risk for prostate cancer.